Julian Davies

USPTO Granted Patents = 22 (Patent Applications = 6)

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 13)

Average Co-Inventor Count = 5.2

ph-index = 7

Forward Citations = 226(Granted Patents)

Location History:

San Diego, CA (US) (2008 - 2013)
La Jolla, CA (US) (2012 - 2022)

Company Filing History:

13 out of 4,442

Eli Lilly and Company

patents

4 out of 27

Applied Molecular Evolution

patents

3 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Abcellera Biologies Inc.

patents

6. 1 out of 1

Abcellera Biologics Inc.

patent

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12172038 - Anti-coronavirus antibodies and methods of use (2024-12-24),

2. 11447541 - Anti-coronavirus antibodies and methods of use (2022-09-20),

3. 11370828 - Anti-coronavirus antibodies and methods of use (2022-06-28),

4. 11267882 - Methods of detecting human IL-21 (2022-03-08),

5. 10913793 - DNA molecules encoding anti-IL-33 antibodies (2021-02-09),

6. 10501536 - Anti-IL-33 antibodies and uses thereof for disease treatment (2019-12-10),

7. 9394362 - IL-21 antibodies and methods of making or using the antibodies (2016-07-19),

8. 9260531 - Anti-c-met antibodies (2016-02-16),

9. 9201074 - Anti-c-Met antibodies (2015-12-01),

10. 8623365 - Aβ binding molecules (2014-01-07),

11. 8530414 - Antibodies to PCSK9 and uses thereof (2013-09-10),

12. 8481037 - Recombinant IL-9 antibodies and uses thereof (2013-07-09),

13. 8398974 - c-Met antibodies (2013-03-19),

14. 8217148 - c-Met antibodies (2012-07-10),

15. 8153125 - CD20 binding molecules (2012-04-10),

Title: Innovations and Contributions of Julian Davies in Antibody Research

Introduction: Julian Davies, a prominent inventor based in La Jolla, California, has made significant contributions to the field of antibody research, as evidenced by his 22 patents. His work primarily focuses on developing anti-coronavirus antibodies, which play a crucial role in combating viral infections such as SARS and COVID-19.

Latest Patents: Among Julian Davies' latest patents are groundbreaking developments in anti-coronavirus antibodies. These antibodies bind to the spike proteins of SARS-CoV and SARS-CoV-2 and are designed for use in treating or preventing conditions associated with these viruses. Additionally, his patents include methods for detecting SARS-CoV or SARS-CoV-2, showcasing the important implications of his research for public health.

Career Highlights: Julian has held pivotal positions at renowned companies, including Eli Lilly and Company and Applied Molecular Evolution. His expertise and innovative approach have positioned him as a key player in the biotechnology sector, particularly in the development of therapeutic solutions to viral infections.

Collaborations: Throughout his career, Julian has collaborated with distinguished colleagues, including Ying Tang and Jeffry Dean Watkins. These partnerships have been instrumental in advancing research and enhancing the efficacy of his inventions.

Conclusion: Julian Davies stands out as a notable inventor within the biotechnology landscape. His dedicated work on anti-coronavirus antibodies not only reflects his innovative spirit but also the potential for substantial contributions to the healthcare field in the fight against infectious diseases. The impact of his inventions will undoubtedly resonate for years to come, as they pave the way for new treatment methodologies and detection strategies.

This text is generated by artificial intelligence and may not be accurate.